Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

BACKGROUND: The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. A physiologically based pharmacokinetic (PBPK) model for pediatric rivaroxaban dosing has been constructed...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Thromb J
Prif Awduron: Willmann, Stefan, Thelen, Kirstin, Kubitza, Dagmar, Lensing, Anthonie W. A., Frede, Matthias, Coboeken, Katrin, Stampfuss, Jan, Burghaus, Rolf, Mück, Wolfgang, Lippert, Jörg
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2018
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6278136/
https://ncbi.nlm.nih.gov/pubmed/30534008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-018-0185-1
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg